Clinical trials: Hyperparathyroidism; Secondary, Renal
Secondary Hyperparathyroidism Due to Renal Causes
Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy
In this study, investigators measure patient's voice frequency, swallowing function, and O2 desaturation of the 6 mins walking test before surgery and 4 months after surgery, to find the increase of voice frequency, and…
- Trial name
- NCT04267965
- Testing
- parathyroidectomy plus bilateral thymectomy and autotransplantation
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Chang Gung Memorial Hospital
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Secondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis
Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients
Background: Calcimimetic therapy has been shown to reduce systemic FGF23 levels, which themselves are associated with left ventricular hypertrophy (LVH) in chronic kidney disease (CKD).
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease Requiring Chronic Dialysis, Left Ventricular Hypertrophy
- Trial name
- EtECAR-HD (NCT03182699)
- Testing
- cardiac MRI, echocardiography with strain, Laboratory tests
- Where
- 2 sites in Austria
- Volunteers
- 62 people
- Sponsor
- Rainer Oberbauer
Hyperparathyroidism; Secondary, Renal
Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment
Chronic kidney disease related mineral and bone disorders (CKD-MBDs) and secondary hyperparathyroidism (SHPT) are observed in most patients with chronic kidney disease on dialysis (CKD-5D).
- Trial name
- NCT04637360
- Testing
- Cinacalcet Tablets, calcitriol
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Min-Sheng General Hospital
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, Chronic Kidney Disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Trial name
- NCT03633708
- Testing
- Etelcalcetide, Standard of Care
- Where
- 43 sites in United States, Argentina and 8 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
- Trial name
- NCT06126016
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active…
- Trial name
- NCT07122401
- Testing
- MT1013, Cinacalcet
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Chronic Kidney Disease-Mineral and Bone Disorder
Neutrophil Gelatinase-associated Lipocalin VS Vascular Calcification in Maintenance Hemodialysis Patients
The goal of this observational study or clinical trial is to learn about the effect of neutrophil gelatinase-associated lipocalin (NGAL) on vascular calcification in maintenance hemodialysis patients with secondary…
- Trial name
- NGAL (NCT05720273)
- Testing
- palicalcitol
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiaoyan Jia
Chronic Kidney Disease
Paricalcitol Injection Phase II Trial
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal…
- Trial name
- NCT00646932
- Testing
- paricalcitol
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Hyperparathyroidism, Secondary
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
This is a multicenter, multiple-dose, single-arm, open-label study to assess the impact on serum corrected calcium levels when switching patients from cinacalcet to etelcalcetide (AMG 416).
- Trial name
- NCT01932970
- Testing
- Etelcalcetide
- Where
- 40 sites in United States
- Volunteers
- 158 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder, Dialysis, Hypocalcemia
- Trial name
- TeriCa (NCT04750460)
- Testing
- Teriparatide
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Secondary Hyperparathyroidism, Chronic Kidney Disease
Trial to Optimize Mineral Outcomes in Dialysis Patients
This trial is designed to determine if the use of a computer algorithm designed to optimize mineral outcomes in dialysis patients increases the number of patients achieving the desired target endpoints for calcium, phosphorus and…
- Trial name
- NCT01100723
- Testing
- Cinacalcet, active vitamin D analogue
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- University of Colorado, Denver
Hyperparathyroidism, Chronic Kidney Disease
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
The hypothesis underlying this study is that phosphate interferes with PTH-mediated calcium reabsorption in the distal nephron and thereby necessitates supranormal [PTH]to maintain normocalcemia in chronic kidney disease.
- Trial name
- NCT01191762
- Testing
- sevelamer carbonate
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kenneth R. Phelps, M.D.
Secondary Hyperparathyroidism
A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
This was a multiple-dose, double-blind, randomized, placebo-controlled study. Chinese subjects residing in Mainland China with chronic kidney disease (CKD) receiving hemodialysis were randomized in a 3:1 ratio to receive 5 mg…
- Trial name
- NCT03283098
- Testing
- Etelcalcetide
- Where
- 5 sites in China
- Volunteers
- 33 people
- Sponsor
- Amgen
CKD, Renal Insufficiency Chronic
The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations
The aim of the study is to assess the association between the calcium and phosphorus balance and the stage of kidney disease measured by creatinine clearence in patients with chronic kidney disease stage 4 and 5.
- Conditions
- CKD, Renal Insufficiency Chronic, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder, Pre-dialysis
- Trial name
- NCT07312981
- Where
- 2 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- University of Copenhagen
Hyperparathyroidism, Secondary
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
This is a multicenter, single-arm, extension study to characterize the long-term safety and tolerability of etelcalcetide in the treatment of Secondary Hyperparathyroidism (SHPT) in adults with Chronic Kidney Disease (CKD) on…
- Trial name
- NCT02102204
- Testing
- Etelcalcetide
- Where
- 228 sites in United States, Australia and 22 more
- Volunteers
- 902 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013…
- Trial name
- NCT06976177
- Testing
- MT1013
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Kidney Failure, Secondary Hyperparathyroidism
Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients
This is a pilot, prospective randomized controlled study with the primary objective to evaluate and compare medical treatment of severe SHPT, namely oral cinacalcet versus surgical treatment, that is, parathyroidectomy with…
- Conditions
- Kidney Failure, Secondary Hyperparathyroidism, Vascular Diseases
- Trial name
- PROCEED (NCT01447368)
- Testing
- Cinacalcet, Surgical total parathyroidectomy with forearm autografting
- Where
- Hong Kong
- Volunteers
- 67 people
- Sponsor
- The University of Hong Kong